In the last three months, 4 analysts have published ratings on OptimizeRx (NASDAQ:OPRX), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 1 | 0 | 0 |
| Last 30D | 3 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.0, a high estimate of $18.00, and a low estimate of $10.00. A 42.86% drop is evident in the current average compared to the previous average price target of $24.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of OptimizeRx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Baldry | Roth Capital | Lowers | Buy | $18.00 | $32.00 |
| Anderson Schock | B. Riley Securities | Lowers | Buy | $11.00 | $28.00 |
| Jeff Garro | Stephens & Co. | Lowers | Equal-Weight | $10.00 | $17.00 |
| David Grossman | Stifel | Lowers | Buy | $17.00 | $21.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OptimizeRx. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of OptimizeRx compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OptimizeRx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on OptimizeRx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
About OptimizeRx
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
OptimizeRx: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining OptimizeRx's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 22.33% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching 2.99%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): OptimizeRx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.65% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): OptimizeRx's ROA excels beyond industry benchmarks, reaching 0.46%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.23, OptimizeRx adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Core of Analyst Ratings: What Every Investor Should Know
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment